Jan 23, 2008 - NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for ZolpiMist(TM) (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia... NovaDel's Press Release-
Wednesday, January 23, 2008
NovaDel, New Drug Application for ZolpiMist(TM) Oral Spray to Treat Insomnia Accepted
Jan 23, 2008 - NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for ZolpiMist(TM) (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia... NovaDel's Press Release-
Tuesday, January 15, 2008
XenoPort and GlaxoSmithKline, Second Phase 3 Restless Legs Syndrome Trial for XP13512/GSK1838262
Jan 15, 2008 - XenoPort, Inc. (Nasdaq:XNPT) and GlaxoSmithKline (NYSE:GSK) announced positive top-line results from a placebo-controlled Phase 3 clinical trial designed to evaluate the potential of XP13512 (GSK1838262) 
to maintain efficacy over the course of nine months in patients with moderate-to-severe primary Restless Legs Syndrome, or RLS... XenoPort's Press Release - GlaxoSmithKline 's Press Release-
Subscribe to:
Posts (Atom)
